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THE SYNTHESIS AND CHARACTERIZATION OF NOVEL RUTHENIUM 
TERPYRIDINE COMPLEXES: REACTIVITY WITH DNA 
by 
Nicolette M. Jonkhoff 
(ABSTRACT) 
Side effects associated with platinum-based anticancer therapies have resulted in the search 
for novel nonplatinum-based metal species. Among the different metal complexes generating · 
interest, ruthenium complexes have shown great potential as anticancer agents. A series of 
mixed ligand ruthenium~ complexes with the formula cis-[Ru(X)(HPB)(OH2)](PF6), where X 
corresponds to either (1) Terpy = 2,2':6',2"-terpyridine; (2) Phterpy = 4'-Phenyl-2,2':6',2"-
terpyridine or (3) Tterpy = 4'-Tolyl-2,2':6',2"-terpyridine, and HPB = 2-(2'-hydroxyphenyl)-
benzoxazole, have been synthesized and structurally characterized. The DNA binding of the 
rutheniumn complexes has been studied using several physical methods including absorption 
spectroscopy and competitive binding displacement assays. The ability of the complexes to 
unwind and I or untwist DNA has also been studied usi~g supercoiled pUC 18 DNA. 
ii 
Table of Contents 
Page 
Abstract ........................ . .. ........... , ................. . .... . .. .. .... . .. .. .. ...... , .... . .. . ii 
List of Figures ............... .. .. ........................... .............. .. .. ..................... . v 
List of Tables ................................. . ............... . ............... . .................... . vi 
List of Graphs ... .......... .... ... ............. ........................ ..... .. .............. ....... . vii 
Ackn.owlcdgements ........... .. ................................................................ . viii 
1. ln'tl'oduction I I I I I I I I I I I I I 1 I e I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I <II I I I I I I I I I I I I I I I <II I I I I I I I I I I I I I I I I I 1 
1.1. Inorg8Jlic chemist:r'y' I I I •• I ' I e I I I I I I I I I • I ' I I I I I I I I I I I I I I I ' I ' I I I I I I I I I I I I I I I ' I ' I I I I I I I I I I I 1 
1.2~ Cispla'tin ......... .. . I • •• •• • •••••• • • I • ••• • I . I • • ••• • • • • • • • •• • •••••• • • • • •• • • • • • • ••• • • • •••• ••• • 1 
1.3. Ru"th.eni.um complexes ........................... I ••••••••••••••• I ••••••••••• I ••••••••• s 
1.4. DNA binding .. . ................ . .... . ............... .. . .... . ................... . ...... . 8 
1.5 I Current project. t I I It I I I I I I t I I t I I tt I I I I I I t I I t' t t 't. I I I I I It It I t I tIt t I I t I It It It t I t I t I I I t I II 8 
2. Experimen1:8.1 .............. I ............... I ........................... I. I ......... ·. I........... 10 
2.1. Materials .... ll t t l llll II IIIII lit• I II Ill 1111111 It I I ltlllllllllt•l II 11111 1 11111111111 1 1 11111 10 
2.2. Techniques and instrumentation...................... . ............ . .............. .. .. 10 
2.3. S-yn1:llese.s......... ... .... .............. .. .............. ............... ....... ..... ....... 12 
2.4. Characteri.za.tion studies ... ~·· ....... . I ••••••••• ~·· ••••••••••••• ~· •• • • ~ · •••••••••••• • I . 15 
3. Results and discussion... ............... .... .. ...... . ... . .... . .......... ... ...... . .. ...... .. 19 
3 .1. S-ynt:h.eses ............ I •• • • ••••••••• • ••••• I ••••••••• • ••• • • I ••••••••• I • • • • • • • • • • • • • • • • • • • • • 19 
3.2. Characterlmtion .......... I.··~·· ....... Ill ••••••••••••••• I ... ~· ................... ~·... 19 
4. Swnmary of fmdings 36 
4.1. Conclusion................................................................................. 36 
111 
4.2. Future work.. ....... ...... ... ... ....... ......... ....... ....... ......... ...... .............. 37 
5. Appendix................................................. ................ ... ......... ......... 39 
6. References............... ...... ... ....... ............. ....... ........ ...... ..... .. .... ....... . 41 
IV 
List of Figures 
Figure No. Page 
1 Molecular structure of an anticancer platinum complex 2 
2 Hydrolysis reaction of cisplatin 3 
3 Binding possibilities between cisplatin and DNA 4 
4 DNA kink induced by the binding of cisplatin 4 
s Molecular structures of anticancer ruthenium complexes 6 
6 Frequently reported polypyridylligands 7 
7 Molecular structures of ligands used in report 9 
8 Molecular strUctures of complexes synthesized in report 10 
9 Synthesis ofRu(Phterpy)(HPB)Cl isomers 14 
10 Molecular orbital diagram for d6 octahedral metal 20 
complex 
11 UV-Vis spectrum of a chloro and aqua complex 21 
12 Cyclic voltammograms 23 
13 Time-lapsed kinetics spectra 24 
14 X-ray crystal structure determination 26 
trans-[Ru(Phterpy)(HPB)Cl](PF 6} 2H20 
IS Ideal absorption titration spectrum 28 
16 Non-ideal absorption titration spectrum 29 
17 Emission spectra of EB bound DNA 30 
18 Sample agarose gel highlighting two common problems 33 
19 Sample agarose gel with presence of bands 35 
20 Reference agarose gel 36 
v 
List of Tables 
Table No. Page 
I Electronic spectral data 21 
2 Electrochemical data 22 
3 Time-lapsed kinetics data 26 
4 Competitive DNA binding data 31 
VI 
List of Graphs 
Graph No. 
1 
2 
Kinetics plot: ln(At • AinQ v. time (s) 
Stem-Volmer plot: IJI v. [Ru]/[DNA] 
Vll 
Page 
25 
31 
Acknowledgements 
First and above all, I praise God, for providing me with the opportunity to study at the 
University of Redlands and granting me the capability to proceed successfully (Phillippians 
4:13). This thesis appears in its current form due to the assistance and guidance of several 
people. I would therefore like to offer my sincere thanks to all of them. 
Dr. Acquaye, my research advisor, for his never-ending enthusiasm, thoughtful guidance and 
critical comments through every stage of this project. 
My thesis committee, for their valuable advice, patience and belief in me. 
The Redlands science faculty for supporting undergraduate research, as well as the 
University of Redlands Summer Research Program for sponsoring my research over the past two 
summers. 
For being sounding boards both inside and outside of lab I acknowledge Sean Currens, 
Phoebe Harpainter, Natasha Kozlyuk, Brandon Piasecki and Edgar Diaz Rosas. I am grateful as 
well for the genuine camaraderie that developed from spending four years with my peers in the 
Stauffer Science Complex. 
And lastly I owe a debt of gratitude to my family. I could not have made it through this 
adventure without them. 
viii 
1. Introduction 
1.1. Inoraanic chemistry 
Active areas of research in inorganic chemistry include organometallic, coordination, 
biological and solid-state chemistry. Biological inorganic chemistry represents a burgeoning 
subdivision that has exploded into the scientific arena in recent years. Here the complementary 
nature of biology and chemistry is witnessed first-hand as both disciplines productively merge to 
tackle a variety of real-world problems. A cursory glance through the Journal of Biological 
Inorganic Chemistry, for instance, reveals both the applicability and comprehensiveness of 
active research projects within this domain. 
1.2. Cisplatin 
One such manifestation of the merger between the disciplines has been the development of 
cisplatin. Rosenberg and co-workers first reported its antitumor activity to Nature in ~969. 1 
Known formally as cis-diamminedichloro platinum (II), this compound serendipitously went on 
to enter into the medical sector as a form of anticancer therapy in the 1970's. This intravenously 
administered agent induces cytotoxic effects mainly through its interaction with cellular DNA. 
Consequently it is often used to combat testicular, ovarian, head and neck cancer.2 While 
derivatives have surfaced, including the second and third generation platin~-based drugs 
carboplatin and oxaliplatin, cisplatin continues to remain a widely used form of 
chemotherapeutic treatment today. 
As its name implies, cisplatin is a platinum-based compound. Although platinum has two 
major valence states, +2 and +4, the square planar structures shown in Figure 1 illustrate the +2 
oxidation state. 
1 
a) b) 
H3N Cl 
' / Pt 
/ ' Cl NH3 
Figure 1. Molecular structure of an active (cis- configuration) versus nonactive (trans- configuration) 
1 anticancer platinum complex. a) cis-diammincdichloro platinum {D) and b) trans-diamminedichloro 
platinum (D). 
Molecular structural differences between cis- and trans- forms can help to explain why only 
the cis- configuration has active anticancer properties. In an effort to establish a causal 
relationship between structure and activity, Thompson and co-workers proposed several general 
characteristic traits. 3 From their work it has been proposed that active. complexes: 1) may have 
either a square planar or octahedral geometry; 2) contain either two cis- monodentate leaving 
groups or one bidentate leaving group; 3) have a ligand exchange rate that is within an 
appropriate range; 4) are arranged such that leaving groups are roughly 3.4 angstroms apart on 
the molecule and /or 5) posses strongly bonded groups that are positioned across the molecule 
from the leaving group. 
While a degree of ambiguity is still inherently present in efforts to differentiate conclusively 
between structure and activity, the proposed characteristics seem to present a reasonable 
argument as to why the cis- structure results in anticancer activity and the trans- structure does 
not.4 Like many facets of science, however, exceptions to "the rule" do exist. Therefore the 
previously articulated structure-activity relationships should be interpreted loosely and in a 
fashion which recognizes the limits to its applications. 
The proposed mechanism for chemotherapeutic action relies upon cisplatin' s affinity for 
cellular DNA. 5•6•7 The anticancer agent is typically combined with a saline solution and, as 
mentioned previously, is administered in an intravenous fashion. Diffusion ushers the neutral 
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complex through the cell wall where, once inside, hydrolysis can occur - as depicted in Figure 2. 
This process enables the metal complex to become "activated", a key step necessary for 
interaction with the nucleophilic sites of DNA. 8 
H20 
cis•PtC12(NHJ)2 ~ 
Figure 2. The hydrolysis of cisplatin inside the cell. [Pt{OH){H20)(NH3) 2t is the most frequently 
occurring species under physiological conditions. Figure adopted from Reedijk and Lohman.5 
The lability of the chloride ligands makes the complex susceptible to ligand substitution. 
Therefore as the chloride ligands become replaced step.:wise with water molecules the complex 
gains an overall charge. This "activated" species can now interact via ligand ·substitution with a 
variety of biological nucleophiles. DNA, however, is believed to be the main target for 
cisplatin. 9 
Figure 3 represents four possible binding modes following the attack of cisplatin on DNA. 
Although the phosphate groups, sugar oxygen atoms and nucleobases of DNA all have electron 
lone pairs which could serve as binding sites for the metal complex, preference is given to the 
nucleobases. 10 ~etic studies further suggest that the complex will first bind covalently to the 
purine base of DNA- notably N7.s Adenine and guanine provide prime nucleophilic binding 
sites for the platinum drug and consequently the major bifunctional adduct formed is the 
intrastrand crosslink between N7 atoms of two adjacent guanine residues.11 This 1,2 intrastrand 
crosslink is not seen in DNA binding studies with transplatin due to sterics. 
3 
Figure 3. Several binding possibilities between cisplatin and DNA.. The favored adduct form is the 1,2 
intrastrand crosslink between two adjacent guanine (G) residues. Figure adopted from Rccdijk and 
Lohman.' 
Although cytotoxicity is an inherently complex process, the main molecular event that 
initiates this process is DNA damage. As expected, cisplatin's binding induces a major change 
in the DNA structure; not only do the bases become unstacked upon binding but, as highlighted 
in Figure 4, a kink in the DNA results. 6 From this point, DNA synthesis can become inhibited 
and RNA transcription can become suppressed 
Figure 4. The binding or'cispl~ ·to DNA induces a kink in the doubie h~Iix. Figure adopted from 
Richards and Rodger.6 
Although DNA modification is proposed to account for the drug's cytotoxic effects, it should 
be noted that cells do possess efficient repair systems. While some of the bifunctional lesions 
4 
induced by the drug may be repaired, it is unclear if cisplatin' s toxic and mutagenic properties 
stem solely from lesions not able to be repaired in a timely manner.' 
There is a fragile balance within oncology between the benefits of chemotherapy and 
correspondingly adverse side effects. Patients prescribed cisplatin are not immune to this teeter 
totter-like situation. And despite apparent effectiveness in the medical sector, it cannot be 
discounted that this platinum-based drug has been known to damage the kidneys, trigger hearing 
loss and induce nausea, vomiting and peripheral neurotoxicity. 12 Issues with regard to patients 
developing resistance to the drug have also surfaced in recent years.13·14 
1.3. Ruthenium complexes 
Detrimental toxicological effects have thus prompted researchers to search for alternatives to 
cisplatin, and interestingly ruthenium complexes have shown great potential as anticancer agents. 
A wide array ofRuu and Rum complexes have been shown to exhibit cytotoxicity, including 
mer-[Rum(terpy)Ch] (where terpy = 2,2':6'2"-terpyridine)15; a-[Run(azpy)2Ch] (where azpy = 
2-phenylazopyridine)16 and organometallic complexes of the type [(776-arene)Run(en)Cl]PF6 
(where en= ethylenediamine). 17 
Notably NAMI-A ([ImH][tram-RuC4(DMSO)(lm)], where 1m = imidazole and DMSO -
dimethyl sulfoxide) was the first rutheniumm complex of its kind to enter into clinical trials in 
1999 due in part to its good antimetastatic activity.18 And in 2003, KP1019 ([IndH][trans-
RuCl4(lnd)2], where Ind = indazole) was introduced into phase I clinical trials against colon 
carcinomas and their metastases. 19 (See Figure 5) Preliminary studies further suggest that some 
ruthenium complexes may be less toxic in comparison to their platinum-based counterparts.20 
5 
Such findings increase ruthenium's attractiveness to the medical sector and give merit to 
continue further study. 
a) b) 
Figure 5. Structures of anticancer ruthenium complexes that have entered into clinical trials a) NAMI-A, 
lmH[trans-RuC4(DMSO)(Im)] and b) KP1019, [IndH][tram-RuC4(Ind)2]. Structures adopted from Tan 
and co-workers.21 
Ruthenium is a group eight transition metal that not only can access a broad range of 
oxidation states, 0 to +8, but can also occupy a wide array of coordination geometries. 22 While 
cisplatin and derivates may have a square planar arrangement, ruthenium complexes can often be 
found to have an octahedral, six-coordinated geometry. Activity of the ruthenium complex can 
thus be influenced by modifying the number and I or types of ligands bound to the transition 
metal center. Additionally, some ligands have been found to induce a degree of chirality to the 
complex. 15 Therefore in comparison to platinum-based complexes, ruthenium complexes have 
two additional binding sites which may allow for new binding modes to the target or even trigger 
a wider spectrum of activity. 
In particular, ruthenium11 complexes containing polypyridyl chelating ligands have been 
studied extensively. Known to uniquely display rich photophysical and redox properties, 
multidentate polypyridylligands are often coupled to ruthenium complexes because they 
enhance DNA binding and photocleaving abilities.23 Their applications, however, are not limited 
just to transition metals. The scope of polypyridyl complexes extends into the fields of 
6 
biochemistry, photochemistry and photophysics. Specifically these complexes have been 
employed to serve as photodynamic therapy (PDT) agents24 and nucleic acid structural probes. 25 
Within the literature there is a reoccurring theme, notably with regard to the types of ligands 
studied. Figure 6 highlights three frequently reported polypyridylligands that can be found 
coupled to ruthenium: 1,10-phenanthroline (phen); 2,2'-bipyridine (bpy) and dipyrido [3,2-
a:2,, ,3 '-c] phenazine ( dppz). These ligands can form strong bonds to ruthenium mainly because 
they have vacant n orbitals that can accept electron density from the ruthenium ion?6 This type 
of n backbonding enables the metal complex to have a relatively high degree of chemical 
stability. 
a) b) c) 
Figure 6. Frequently reported heterocyclic ligands that are often coupled to ruthenium a) phen; b) bpy 
and c) dppz. 
Due in part to diverse DNA-binding modes, ruthenium. II complexes containing the bidentate 
polypyridylligand bpy have been found to be ideal DNA probes.27 Under particular conditions 
some bpy complexes have also been reported to have efficient DNA photocleaving abilities.28 
Additionally, ruthenium complexes incorporating the dppz ligand have also been· noted to bind to 
and photocleave DNA. Ambroise and Maiya, for instance, reported that the· influence of the 
dppz ligand enabled their metal complex to exhibit interesting "electro-photo switch" effects. 29 
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1.4. DNA binding 
Ruthenium complexes containing polypyridylligands, as well as aqua or chloro groups, have 
been reported to bind to DNA.30 In contrast to the stable pyridyl groups, aqua and chloro ligands 
are typically noted to be leaving ligands.31 
Generally ruthenium11 complexes can bind-to DNA with intercalating, groove binding and I 
or electrostatic binding modes. The mechanism of action for a metal complex to bind to DNA, 
however, is dependent both on the structure of the ruthenium complex and on the structure of the 
various ligands. 32 In order to deduce the mode, or strength, of action between the complex and 
the DNA, competitive binding displacement assays as well as cleavage gel assays, among others, 
can be carried out. It is useful as well to note that ruthenium polypyridyl complexes have good 
light absorbing properties. They can absorb throughout much of the ultraviolet and visible 
spectrum. Thus their light absorbing properties provide another useful way to monitor the 
interaction between the complex and DNA. 
1.5. Current proiect 
In this report the synthesis, characterization, electrochemical properties and DNA binding of 
a series of mixed ligand ruthenium11 complexes of the type cis-[Ru(X)(HPB)(OH2)](PF6), where 
X corresponds to either (1) Terpy = 2,2':6',2"-terpyridine; (2) Phterpy = 4'-Phenyl-2,2':6',2"-
terpyridine or (3) Tterpy = 4'-Tolyl-2,2':6',2"-terpyridine, and HPB = 2-(2'-hydroxyphenyl)-
benzoxazole, are explored (Figures 7 and 8). By beginning with the basic terpyridine ligand and 
adding various electron donating substituents (such as a phenyl or tolyl group) we hope to assess 
hovy the overall chemistry of the ruthenium complex is affected. 
8 
The rationale behind the particular design of these complexes is that tridentate ligands such 
as terpyridine and its extended derivatives have been less studied in this application. DNA 
binding properties of these complexes have also yet to be studied extensively, although 
terpyridine is noted to be an intercalating ligand.33 Additionally, these terpyridine ligands are 
attractive in that they have a planar aromatic system which projects away from the metal center; 
they are also freely available and relatively easy to synthesize. 
b) 
~\r  I N 
· o 
a) 
c) d) 
Figure 7. Ligands used in this report a) terpyridine (Terpy); b) phenyl terpyridine (Phterpy); c) tolyl 
terpyridine (Ttcrpy) and d) 2-(2'-hydroxyphenyl)-benzoxazole (HPB or '~). 
Various electron donating substituents (phenyl and tolyl group) were added to the basic terpyridinc ligand 
in order to assess how the overall chemistry of the ruthenium complex was affected. Note that tcrpyridine 
is reported to be an intercalating ligand. 33 
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a) b) 
Figure 8. Three complexes synthesized in this report a) cis-[Ru{Terpy)(HPB){OH2)]; 
b) cls-[Ru{Phterpy)(HPB){OH2)] and c) cis-[Ru{Ttcrpy)(HPB)(OH2)]. 
2. Experimental 
2.1. Materials 
All solvents and materials used for preparation were reagent grade, purchased from the 
Sigma Aldrich Company (St. Louis, MO) and used as received without further purification. Calf 
thymus (Cn DNA and plasmid DNA (pUC18) were also purchased from Sigma Aldrich. 
2.2. Techniques and instrumentation 
Deionized water was used to prepare all buffers. Phosphate buffer (pH 7 .0) was prepared by 
dissolving sodium phosphate, NaH2P04, (600 mg) in approximately 450 mL water. The solution 
was titrated to pH 7.04 with strong acid or base as needed and the final volume was made up to 
500 mL. Tris base buffer (10 mM, pH 7.1) was prepare.d by dissolving Tris base (300 mg) in 
approximately 100 mL water. The solution was titrated to pH 7.1 with sulfuric acid and the final 
volume was made up to 150 mL. 
A solution ofCT-DNA was prepared by dissolving one frozen DNA pellet in a fresh solution 
of phosphate buffer (25 mL, pH 7.0). The DNA stock solution was not used for any reactivity 
studies until it was homogenous in composition. The freshly prepared solution was stored in the 
10 
refrigerator until needed and for optimal results the solution was typically used within five days. 
A plasmid DNA solution was prepared by diluting the frozen pUC18 DNA sample with Tris 
base buffer (20 ~L) and was stored in the freezer until needed. A 1% stock solution of ethidium 
bromide (EB) (2.2536 x 10"2 M) was prepared and diluted as needed using deionized water. 
Absorption measurements were recorded using a 1.0 em quartz cuvette on a Shimadzu 
PharmSpec 1700 UV-Vis Spectrophotometer. A solution of CT -DNA in phosphate buffer (pH 
7.0) gave a ratio ofUV absorbance at 260 and 280 nm of about 1.8-1.9, indicating that the DNA 
was sufficiently free ofprotein.34 The concentration ofCT-DNA was determined by using the 
molar absorption coefficient (6600 ~1cm'1) at 260 nm.35 
UV-Vis spectra were recorded on a Jasco V -530 UV-Vis Spectrophotometer which was 
equipped with a thermostated Fisher Scientific lsotemp 3028 temperature control compartment. 
The reactions were recorded in a 1.0 em quartz cell and analyzed using Spectra Manager 
software. The substitution of the aqua ligand was monitored by following the change in 
absorbance between 720-765 nm. 
Cyclic voltammetry studies were performed in dichloromethane using a BAS CV -Solv 
voltammetric analyzer. A single compartment cell with a three electrode set-up was used which 
consisted of a platinum disk working electrode, platinum wire auxiliary electrode and an 
Agl AgCl reference electrode. The platinum disk working electrode was polished using alumina 
before each use. The supporting electrolyte was tetrabutylammonium hexafluorophosphate, 
BU4NPF 6 (0.1 M). Samples were purged with nitrogen gas for two-three minutes before scans 
and scans were performed under a nitrogen gas atmosphere at room temperature. The scan rate 
for each measurement was 100 mV/s. 
11 
Fluorescence spectra were taken in 1.0 em quartz cells and recorded using a Jasco FP-750 
Spectrofluorometer. 
pH measurements were performed using an Accumel pH meter which was calibrated using 
three pre-made standard buffer solutions (pH 4, 7 and 1 0). 
Elemental analyses were performed by Galbraith Laboratories, Inc. (Knoxville, TN). 
2.3. Syntheses36 
2.3.1. RuOOCl.1 (where X= Terpy; Phterpy; Tterpy) 
A solution containing RuCl3 · 3H20 (540 mg) and SO mL ethanol was degassed with nitrogen 
gas for five minutes. 2,2':6'2"-terpyridine (560 mg) was added and the solution was refluxed 
under nitrogen· gas for four hours. The mixture was allowed to cool and the brick red precipitate 
was washed several times with ethanol until the washing was colorless. The product was dried 
under vacuum for one day. A similar procedure was used for the Phterpy and Tterpy complexes. 
Yield: 870 mg- 2120 mg. 
Ru(Terpy)Cl] yield: 870 mg 
Ru(Phterpy)Cl] yield: 900 mg 
Ru(Tterpy)Cl] yield: 2.120 g 
2.3 .2. cis- and trans-[RuOOCHPBlCIJ (where X = Terpy; Phterpy; Tterpy) 
Ru(terpy)Ch (400 mg) was added to a mixture of ethanol and deionized water, 40 mL and 15 
mL, respectively. The solution was degassed with nitrogen for five minutes. 
2-(2'-hydroxyphenyl)-benzoxazole (200 mg) was dissolved in 15 mL hot ethanol and added to 
the ruthenium solution. Triethylamine, 1 mL, was added and the solution was refluxed under 
12 
nitrogen gas for four hours (Figure 9). After cooling, the solution was filtered and the product 
was washed with ethanol until the washing was colorless. The solid was then washed with S m.L 
deionized water, followed by 10 mL ethanol and 10 mL ether. The solid product (trans-) was 
allowed to air dry. A similar procedure was used for the Phterpy and Tterpy complexes. Yield: 
274 mg -700 mg. 
· trans-Ru(Terpy)(HBP)Cl yield: 274 mg 
trans-Ru(Phterpy)(HBP)Cl yield: 300 mg 
trans-Ru(Tterpy)(HBP)Cl yield: 700 mg 
The filtrate was rotary evaporated to dryness. 20 mL deionized water was added and the 
mixture was sonicated for two minutes. The solution was filtered and washed several times with 
deionized water. The product (cis-) was allowed to air dry. A similar procedure was used for 
the Phterpy and Tterpy complexes. Yield: 78 mg - 233 mg. 
cis -Ru(Terpy)(HBP)Cl yield: 233 mg 
cis -Ru(Phterpy)(HBP)Cl yield: 100 mg 
cis -Ru(Tterpy)(HBP)Cl yield: 78 mg 
13 
• 
0 N 
+llfsNRC 
Figure 9. Synthesis ofthe Ru(Phterpy){HPB)Cl isomers. 
2.3.3. cis-[RuOO(HPB)(H2.0)J(PFiJ (where X= Terpy(l); Phterpy(:Z); Tterpy(3)) 
ci.r-Ru(Terpy)(HPB)Cl (1 00 mg) was added to a mixture of deionized water and acetone, 30 
mL and 20 mL, respectively. Silver hexafluorophosphate, AgPF6, (130 mg) was added and the 
solution was refluxed under nitrogen gas for one hour. After cooling to room temperature, the 
solution was further cooled in an ice bath for a half hour. A fine glass frit was used to filter the 
solution. Ammonium hexafluorophosphate, N}4PF6, (1.0 g) was added to the filtrate and the 
solution was stored in the refrigerator overnight. The dark green microcrystals were then filtered 
with 5 mL cold deionized water. l'Jle product was allowed to air dry and was characterized to be 
complex 1. A similar procedure was used for the Phterpy and Tterpy complexes, characterized 
to be complexes 2 and 3, respectively. Elemental analysis data was recorded for complex 2. 
Yield: 104 mg M 1 SO mg. 
(1) cis -[Ru(Terpy)(HBP)(H20)](PF6) yield: 104 mg 
(2) cis -[Ru{Phterpy)(HBP)(H20)](PF6) yield: 120 mg 
(3) cis -[Ru(Tterpy)(HBP)(H20)]{PF6) yield: 150 mg 
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2.4. Characterization studies 
2.4.1. UV-Vis 
The UV-Vis spectra of the cis- and trans-Ru(X)(HPB)Cl complexes, as well as the cis- and 
trans-[Ru(X)(HPB)(H20)](PF6) complexes, were recorded in dichloromethane between 235 and 
900nm. 
2.4.2. Cyclic voltammetry 
The electrochemical characteristics of complexes 1, 2 and 3 were investigated using a cyclic 
voltammetry technique, as previously described in section 2.2. 
2.4.3. Time-lapsed kinetics 
Ruthenium complex 1 (6 mg) was dissolved in phosphate buffer (25 m.L, pH 7.0). CT-DNA 
(0.75 m.L) was added to the ruthenium solution (0.25 mL) and an absorption spectrum was 
recorded overnight in ninety ininute intervals between 400-900 nm. The temperature was kept 
constant at 37 °C. A similar procedure was carried out for complexes 2 and 3. 
2.4.4. X-ray en stal structure determination 
X-ray crystal structure determination was performed by Dr. FookS. Tham at the Department 
of Chemistry, University of California, Riverside, CA. A black fragment of a prism (0.47 x 0.43 
x 0.23 mm3) was used for the single crystal x-ray diffraction study of C3..H23N4(hClRu • PF6 · 
[H20]1.2l (sample hal3_0m). The crystal was coated with paratone oil and mounted on to a 
cryo-loop glass fiber. X-ray intensity data were collected at 100(2) K on a Bruker APEX2 
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platform-CCD x-ray diffractometer system (Me-radiation, A== 0.71073 A, 50KV/40mA 
power). 37 The CCD detector ~ placed at a distance of 5.0670 em from the crystal. 
A total of 3600 frames were collected for a sphere of reflections (with scan width of 0.3° in 
m, starting m and 29 angles of -30°, and cj) angles of0°, 90°, 120°, 180°, 240°, and 270° for every 
600 frames, 20 sec/frame exposure time). The frames were integrated using the Broker SAINT 
software package and using a narrow-frame integration algorithm.38 Based on a triclinic crystal 
system, the integrated frames yielded a total of 35319 reflections at a maximum 29 angle of 
59.14° (0.72 A resolution), of 'Yhich 8852 were independent reflections (Rint == 0.0153, R.ia == 
0.0125, redundancy= 4.0, completeness = 99.7%) and 8459 (95.6%) reflections were greater 
than 2a(I). The unit cell parameters were, a= 10.1967(3) A, b == 11.9503(4) A, c = 14.1934(5) 
A, a= 112.8086(4)0 , ~ = 91.7830(4)0 , y = 95.5838(4)0 , V == 1582.24(9) A3, Z = 2, calculated 
density De= 1.727 g/cm3. Absorption corrections were applied (absorption coefficient J.L == 0.711 
mm"
1
: maximin transmission = 0.8541/0.7319) to the raw intensity data using the SADABS 
program.39 
The Broker SHELXTL software package was used for phase determination and structure 
refinement. 40 The distribution of intensities (E2 -1 = 0. 853) and no systematic absent reflections 
indicated two possible space groups, P-1 and Pl. The space group P-1 (#2) was later determined 
to be correct.. Direct methods of phase determination followed by two Fourier cycles of 
refinement led to an electron density map from which most of the non-hydrogen atoms were 
identified in the asymmetry unit of the unit cell. With subsequent isotropic refinement, all of the 
non-hydrogen atoms were identified. There was one cation of C34H23N402ClRu, one anion of 
PF 6, and 1.21 water molecules present in the asymmetry unit of the unit cell. The water 
molecules were hydrogen bonded to the oxygen, fluorine and chlorine atoms. 
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Atomic coordinates, isotropic and anisotropic displacement parameters of all the non-
hydrogen atoms were refined by means of a full matrix least-squares procedure on p2, The H-
atoms were included in the refinement in calculated positions riding on the atoms to which they 
were attached, except the H-atoms involved in hydrogen bonding. The refmement converged at 
R1 = 0.0229, wR2 = 0.0599, with intensity, 1>2a(l). The largest peak/hole in the final difference 
map was 1.569/-0.387 e!A3• The high electron density peak (1.569 e!A3) next to the Ru-atom 
was probably due to absorption corrections error. The crystallographic data are summarized in 
Appendix 1 and the structured described is in Figure 14. 
2.4.5. Absomtion spectral study 
Absorption titration of the ruthenium complex was performed by loosely following a 
procedure published by Gao and co-workers.27 The concentrations of the CT-DNA and 
ruthenium solution were adjusted such that the DNA was about ten times more concentrated than 
the ruthenium solution. Keeping the ruthenium solution volume constant (0.2 mL, 7.61 x 
lo-s M) and the total solution volume at 1 mL, increasing amounts ofCT-DNA were added. 
Phosphate buffer (pH 7.0) was added as needed to keep the total volume of each trial constant. 
Complex-DNA solutions were incubated in a warm water bath at 37 °C for ten minutes prior to 
each UV-Vis scan between 400-900 mn. Phosphate buffer was used in the reference cell. 
2.4.6. Comoetitive binding displacement with ethidium bromide ( EB l 
CT -DNA competitive binding experiments with EB were carried out in phosphate buffer (pH 
7 .0). As suggested by Tan and co-workers, the ratio of CT -DNA to EB was fixed for each trial 
([CT-DNA]/[EB] = 5) and the concentration of the ruthenium complex was varied accordingly 
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([Ru] = 0-300 ~M). 41 The components were mixed· in a vial by repeated inversion upon addition 
of the ruthenium solution to a mixture of CT-DNA and EB. Solutions were allowed to sit at 
room temperature for twenty minutes before being analyzed by fluorometry. The excitation 
wavelength was 537 nm and the emission range was set between 500-700 nm. 
The spectra were further ~yzed using the Stern-Volmer equation (1 ), where Ia and I are the 
fluorescence intensities in the absence and presence ofthe complexes, respectively, K5vis the 
Stern-Volmer quenching constant, and r is the ratio of the .total concentration of the complex to 
the CT-DNA ([Ru]/[CT-DNA]). 
(1) 
2.4. 7. DNA cleavage 
A slightly modified procedure published by Deshpande and co-workers was used to analyze 
the binding of the metal complexes to supercoiled pUC18 DNA via agarose gel electrophoresis.42 
Plasmid DNA (2 ~L) was treated with different concentrations of the metal complex (0-10 ~M) 
and the mixtures were incubated briefly for one hour in the dark at 37 °C. After incubation, the 
reactions were quenched by the addition of 6X loading dye (2 ~L). The samples were then 
loaded into the wells and subjected to electrophoresis for ninety minutes at 60 V on 1.2 % 
agarose gel stained with EB in TAB buffer. The gel was visualized by UV light and 
photographed for analysis. 
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3. Results and discussion 
3 .1. Syntheses 
Mixed ligand ruthenium0 complexes with the formula cis-[Ru(Terpy)(HPB)(OH2)](PF6) 1, 
cis-[Ru(Phterpy)(HPB)(OH2)](PF6) 2 and cis-[Ru(Tterpy)(HPB)(OH2)](PF6) 3 have been 
synthesized. 
Elemental analyses cis-[Ru(Phterpy)(HPB)(OH2) ](PF 6)2 · 2H20 [RuC34H2sN403P2F 12 · 2H20] 
calculated (found): C, 42.33 (42.05); H, 3.04 (3.09); N, 5.81 (5.71). 
Elemental analyses trans-[Ru(Phterpy)(HPB)(OH2)](PF6)·2H20 [RuC3~2sN403PF6·2H20] 
calculated (found): C, 49.81 (49.45); H, 3.08 (3.11); N, 6.84 (6.69). 
3 .2. Characterization 
3.2.1. UV-Vis 
In order to study the light absorbing properties of the ruthenium complexes, an electronic 
absorption spectrum was recorded for each metal complex in dichloromethane. Specifically it 
was of interest to note any changes between the absorption spectrum of the chloro complex and 
the absorption spectrum of the aqua complex, as this would be used to later help interpret data 
from reactions which combined the metal aqua complex with CT-DNA. 
In order to properly assign each band to a particular transition it was necessary to consider 
the molecular orbital diagram for a d6 octahedral metal complex (Figure 10). The most 
important orbitals in major electronic transitions to make note of are the filled metal 1r-orbital 
(HOMO) and the unfilled ligand 1r• -orbital (LUMO). 
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Figure 10. Molecular orbital diagram for a d6 octahedral metal complex. Shaded boxes refer to .a filled 
molecular orbital and arrows represent common transitions. MLCT= metal to ligand charge transfer; 
LMCT=ligand to metal charge transfer. 
Table 1 highlights the electronic spectral data for the Phterpy complexes synthesized in this 
report. The electronic spectra for the two chloro isomers, Ru(Phterpy)(HPB)Cl, are similar, with 
only slight variations in the A.max· Notably the chloro isomers feature two high energy transitions 
in the ultra violet region between 240-350 nm which likely correspond to the n-n•transitions in 
both the Phterpy and HPB ligands. 43 It is difficult however to detennine which ligand directly 
corresponds to which transition in this region. Nonetheless, these two bands were found to be 
present in the absorption spectrum of the aqua complexes as well. This is to be expected since 
both the chloro and aqua complexes contain the Phterpy and HPB ligands. The chloro 
complexes also feature two lower energy transitions in the visible region between 400 and 600 
run which can be attributed to a metal to ligand charge transfer (MLCT) from the d-orbital of the 
metal complex to the n•-orbital of the Phterpy and HPB ligands.44 
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The appearance of a broad band in the visible region at about 750 nm was a striking feature 
evident only in the spectra for the two aqua isomers, [Ru(Phterpy)(HPB)(H20)](PF6)2 (Figure 
11). The introduction of a broad band in the aqua complex spectrum was-consistent with results 
obtained by Claustro and co-workers for similar terpyridine complexes. 36 As suggested by 
Balzani and co-workers, these bands likely correspond to ligand to metal charge transfers 
(LMCT).45 
Table 1. Electronic spectral data 
Complex Amax (log E) 
cis-Ru(Phterpy)(HPB)Cl 281 (4.69); 322 (4.26); 400 (4.11); 583 (3.94) 
trans-Ru(Phterpy)(HPB)Cl 284 (4.61); 323 (4.4); 402 (4.11); 581 (3.88) 
cis-[Ru(Phterpy)(HPB)(H20)](PF6)2 (l) 286 (4.52); 335 (4.37); 406 (3.84); 757 (3.64) 
trans-[Ru(Phterpy)(HPB)(H20)](PF 6) 286 (5.33); 334 (5.04); 430 (4.48); 720 (4.36) 
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Figure 11. UV-Vis spectra of a chloro and aqua complex recorded in dichloromethane. The chloro complex (on the 
left) and the aqua complex (on the right) both have similar absorption bands between 200 and 500 nm. Note however 
that the chloro complex does not have an absorption band in the 750 nm region while the aqua complex does. In other 
words, substitution of the chloride ligand with an aqua ligand results in the appearance of a new peak around 750 nm. 
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3.2.2. Cyclic voltammetry 
The electrochemical behavior of the complexes were studied in dichloromethane. Table 2 
highlights the results. The cyclic voltammograms show one distinct redox process occurring 
which suggests that the samples are pure (Figure 12). The corresponding E112 for the reversible 
couple of cis-Ru(Phterpy)(HPB)Cl and cis-[Ru(Phterpy)(HPB)(H20)](PF6)2 are 293 mV and 
494.5 m V, respectively. The corresponding E112 for the reversible couple of trans-
Ru(Phterpy)(HPB)Cl and trans-[Ru(Phterpy)(HP8)(H20)](PF6)2 are 171.2 mV and 163 mV, 
respectively. 
Table 2. Electrochemical data 
Complex E112 (mV) 
cis-Ru(Phterpy)(HPB)Cl 293 
trans-Ru(Phterpy)(HPB)Cl 171.5 
cis-[Ru(Phterpy)(HPB)(H20)](PF 6)2 (2) 494.5 
trans-[Ru(Phterpy)(HPB)(H20)](PF 6) 163 
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Figure 12. Cyclic voltammograms of two aqua isomers, [Ru(Phterpy)(HPB){H20)](PF6). 
3.2.3. Tim.e-laosed kinetics 
In order to assess if each metal aqua complex interacts with CT -DNA, a time-lapsed kinetics 
experiment was performed. The spectrum of complex 1 in phosphate buffer (pH 7 .0) with CT-
DNA is shown in Figure 13. From previous UV-Vis spectroscopic experiments, the addition of 
the aqua ligand to the metal complex resulted in the formation of a band in the visible region 
(-750 nm) of the spectrum (Figure 11). As to be expected, Figure 13 features the characteristic 
aqua absorption band in the visible region at 734 nm. 
The experimental conditions involved following the reaction between the metal aqua 
complex and CT -DNA with time. As the reaction progressed, the absorption band at 734 nm 
decreased. Because there were only two components in the reaction cuvette, the decrease in 
absorbance gestured to the fact that there was some type of interaction occUlTing between the 
metal complex and CT -DNA. Note that the metal complex has a relatively high degree of 
stability and thus degradation of the complex is unlikely to account for the observed decrease in 
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absorbance. It is probable however that because aqua ligands are reported to be good leaving 
ligands, the CT-DNA is able to interact with the metal complex in such a way that results in the 
loss of the aqua ligand and, in turn, triggers a reduction in the absorbance of the solution. 31 
Similar time-lapsed kinetics spectra were obtained for complexes 2 and 3, and it was decided 
that further experiments ought to be carried out in order to clarify the interaction between the 
met8I aqua complexes and CT -DNA. 
l 
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Figure 13. Time-lapsed kinetics spectra of complex! {0.25 mL, 6.645 X 10-4M) and CT-
DNA {0.75 mL, 2.588 X 10-4M) measured in phosphate buffer (pH 7.0). Scans were 
recorded overnight in ninety minute intervals at 3 7 °C. The aJTOWS show how the 
absorbance changes with time. Similar spectra were obtained for complexes l and 3. 
In order to quantitatively determine the rate of interaction between the metal aqua complex 
and CT -DNA, the change in absorbance at 734 nm was analyzed. Assuming that the reaction 
was pseudo-first order under the experimental conditions, a plot ofln(At- Ami) v. time (s) was 
used to describe the kinetics (Graph 1). The plot was expected to be linear with a slope of -kob1, 
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where At was the absorbance at time t, Aint was the absorbance at infmite time and k was the 
observed pseudo-first order rate constant. 
As highlighted in Table 3, the observed rate constants follow the order of complex 2 > 1 > 3. 
The addition of the electron donating phenyl group (complex 2) does appear to positively 
enhance the rate of reaction between the complex and DNA; complex 2 has a higher observed 
rate constant than the unsubstituted terpyridine complex 1. However if the trend for the observed 
rate constants were to be based solely on electronic effects, we would expect that the addition of 
an even stronger electron donating tolyl group (complex 3) would have the highest observed rate 
constant. Surprisingly, complex 3 has the smallest observed rate constant. We propose that the 
addition of the methyl group (complex 3) is causing unfavorable steric problems that hinders the 
interaction between the complex and CT-DNA. 
0 - · ... r---. 
10000 20000 !0000 40000 50000 
-o.s 
· 1 - -
i -1.5 
c 
. 
:f r .z. 
·2.5 
· 3,5 
y • ·Z,I0021!!·05M • 9,3113E•Ol 
Rz. 9.11431!-01 
50000 70000 110000---;;;100 
• 
Graph 1. Analysis of time--lapsed kinetics data (l= 734 nm). Plot ofln(At -Au,c) v. time (s) for 
complex 1 where slope = -kot,.. Similar plots were obtained for complexes l and 3. 
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Table 3. Summary of time-lapsed kinetics data, A.= 734 nm~ derived 
from the plot ofln(At- Ainf) v. time (s) where slope= -kobs· 
Complex Pseudo-first order rate constant~ kobs (s"') 
1 2.600X 10"" 
l 3.473 x to·) 
3 2.467 X 10·;, 
3.2.4. X-rav crystal structure determination 
I 
The molecular structure oftrans-[Ru(Phterpy)(HPB)Cl](PF6) · 2H20 has been established by 
single crystal x-ray diffraction. An ORTEP drawing of the complex is shown in Figure 14. 
Selected interatomic distances (A) and angles C') for the complex are reported in Appendix l. 
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Figure 14. X-ray crystal structure determination of tram-[Ru(Phterpy)(HPB)Cl](PF6)·2H20. Crystal data 
are given in Appendix 1 and selected bond angles and bond lengths are listed in Appendix 2. 
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The crystal structure shows that the complex has a slightly distorted octahedral geometry 
around the ruthenium center and as a result, the Ru-N bond lengths of the Phenyl terpyridine 
ligand are not uniform. Despite the range from t".9606 to 2.0882 A, this was found to match well 
with Ru-N bond length values reported for other ruthenium terpyridine complexes. 36•46 The 
central Phenyl terpyridine ligand was also found to be bound trans to the imine nitrogen N ( 4), 
with an observed N(4)-Ru-N(2) angle of 177.01°. The other two terminal pyridine rings were 
found to be bound to the ruthenium center at angles N(2)-Ru-N(3) of79.69° and N(1)-Ru-N(2) 
of 80.04°.· Structural constraint is likely preventing the rings from binding to the ruthenium 
center at an ideal 90° angle. 47 
The Ru-Cl bonq was found to be 2.3536 A, while the bond length between the ruthenium and 
phenolic oxygen ofthe HPB ligand was found to be considerably shorter, 1.9646 A. This Ru-0 
distance, however, was found to be comparable (1.9823 A) to that of a similar ruthenium 
terpyridine complex, [Ru(terpy)LCl]Cl04, which incorporated a phenolic Schiff base ligand, L.47 
3.2.5. Absorntion titration studies 
Complex 1 was titrated with varying concentrations ofCT-DNA and the change in the 
absorption spectrum at different [DNA] is shown in Figure 15. Upon increasing concentration 
of the CT -DNA, there is a clear decrease in absorbance. Additionally there is a shift of about 23 
nm to longer wavelength. According to several authors, such an observation is indicative of an 
intercalation association between the complex and CT-DNA.29•48•49.5° 
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Fipre 15. The overlay ofthe absorption titrations ofl with CT-DNA ([DNA]= 0-100 JlM} in 
phosphate buffer. Similar spectra have not been able to be obtained for complexes l and 3. 
When complexes 2 and 3 were titrated with varying concentrations of CT -DNA, the resulting 
spectra were quite erratic. Initially upon increasing the concentration ofCT-DNA there was a 
decrease in absorbance, followed then by a drastic increase in absorbance (Figure 16). It is 
likely that experimental conditions are not ideal for these complexes. 
28 
, 
0.1 -
100 
0 • 
-----~·- -------
eoo 110 
Fi1ure 16. An absorption titration ofl with CT-DNA ([DNA]= 0-100 JJM) in phosphate buffer. The 
changes in absorbance do not follow any particular order upon increasing the concentration of DNA. 
Similar spectra were also obtained for complex 3. 
3.2.6. Competitive binding displacement with ethidium bromide CEB) 
Although not a direct way to determine the binding mode between a metal complex and CT-
DNA, per say, a competitive binding displacement assay is, nonetheless, a common experiment 
reported in the literature.' 1•52 Its primary purpose is to measure the ability of a metal complex to 
affect the EB fluorescence intensity of an EB-DNA complex. Recall that although EB alone 
moderately emits, when it is combined with CT-DNA the emission intensity is greatly 
magnified. Therefore if a metal complex is found to have a .high affinity for CT-DNA and is 
added to an EB-DNA solution, the metal will try to bind to DNA, potentially kicking out EB 
from the EB-DNA solution. IfEB is displaced from the EB-DNA solution a decrease in the 
emission intensity will be observed. Note that this can only happen though if the metal complex 
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binds much more strongly to the CT-DNA than EB does. In other words, this experiment 
enables one to determine the extent at which the metal complex can competitively kick out EB 
bound to CT-DNA. 
As was expected, upon adding complex 1 (0-300 JJ.M) to CT-DNA pretreated with EB ([CT-
DNA]/[EB] = 5) the emission intensity of the DNA-bound EB solution (,t•x. 537 nm) decreased 
(Figure 17). Similar spectra were also obtained for complexes l and 3. The clear decrease in 
emission intensity upon addition of the complex suggested that metal complex efficiently 
competes with EB for binding positions on the CT -DNA. As proposed by other research teams, 
the decrease in emission intensity may be attributed to the complexes' ability to displace EB that 
has intercalated itself in between the base pairs of the DNA structure.21•53 
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Figure 17. The overlay of the emission spectra of EB bound to DNA in the presence of complex 1. [CT-
DNA]/[EB]-= S; [Ru] = 0-300 J.LM. The arrow shows the change in emission intensity upon increasing 
concentration of the metal complex. Similar spectra were obtained for complexes 2 and 3. 
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In order to further analyze the emission intensity spectrum, the Stem-Volmer equation (1) 
was used to derive a quenching plot, IJI v. [Ru]/[DNA] (Graph 2). From the slope, K.v = 0.482 
for complex 1 which was found to be higher than 2 <Ksv = 0.401) and 3 (Ksv = 0.237), measured 
all under the same conditions (Table 4). Based on the relative order of quenching constants (1 > 
2 > 3) it is proposed that the addition of an electron donating substituent does not enhance the 
complexes' ability to quench fluorescence. 
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Graph l. Analysis _of emission spectral data. Plot ofiJI v. [Ru]/[DNA] for complex. I where slope= 
Stem-Volmer quenching constant, K.v· 
Table 4. Summary of competitive DNA binding study. Data derived 
from the plot oflc/1 v. [Ru]/[DNA] where slope= the Stem-Volmer 
quenching constant, K.v. 
Complex Ksv from Stern-Volmer plot 
1 0.482 
2 0.401 
3 0.237 I 
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3.2.7. DNA cleavag.,e 
Agarose gel electrophoresis is a standard method used to study the structural effects of drug-
DNA binding. Under the influence of an electric field, this technique fractionates 
macromolecules on the basis of their movement through a gel.. Thus the size and charge of the 
macromolecule will greatly influence movement through the media. Small molecules are 
expected to progress further through the agarose matrix and with a faster rate of migration, while 
larger molecules will have a slower rate of migration. Therefore if a metal complex binds to a 
DNA molecule and the interaction induces a change in the mass, charge and I or tertiary structure 
of the DNA molecule, the migration of the DNA through the gel will be affected. 
It is important to consider as well that DNA has three common forms: superhelical circular 
(form I); nicked circular (form II) and linear (form lll).54 The various forms of the DNA will 
migrate at different rates through the gel; linear form III typically has the slowest migration rate 
while supercoiled form I migrates the fastest. Because the gel can be visualized under UV light, 
any changes in the electrophoretic mobility of the DNA can be clearly assessed. 
The interaction of complexes 1-3 with closed, superhelical plasmid pUC18 DNA was 
monitored using agarose gel electrophoresis. The complexes were incubated with DNA for one 
hour and then subjected to gel electrophoresis for ninety minutes at 60 V. 
Many problems arose with this experiment. Gel preparation proved to be problematic. It 
was necessary for each gel to be made, however often times gels were prepared several days in 
advance and stored covered in buffer in the refrigerator. When the samples were ready to be 
analyzed the pre-made gel was removed from the refrigerator, samples were loaded into the 
wells, an electric field was applied and after a period of time the gel was visualized under UV 
light. 
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The reader will note that the sample gel image, as shown in Figure 18, has many white 
specks throughout This contamination, which was often seen during beginning trials, detracts 
from the overall quality of the gel and is likely due to the fact that the agarose was not fully 
dissolved in the TAE buffer. Although the agarose and buffer solution were heated in the 
microwave for at least a minute, it is likely that the solution was poured into the loading 
apparatus before it was uniform in composition. As a result, any bands that might have been 
able to be visualized were compromised by the presence of undissolved agarose particles. The 
fact that the gels were made several days in advance also did not help the situation and it was 
decided that all gels should be meticulously prepared the day of analysis. 
LanesABCD EF 
Figure 18. Sample gel image highlighting several problems 1) white specks throughout and 2) smearing 
in each lane with no clear bands in s~ple lanes A through E. Note that lane F corresponds tria 100 base 
pair marker. 
Figure 18 highlights another problem often encountered: smearing in the sample lanes (note 
that the problem is more visible in.the actual photograph as opposed to the scanned image 
included in this report). Although lanes A through E were loaded with a solution containing the 
metal complex, plasmid DNA and 6X loading dye, the only visualized bands were those from the 
base pair marker in lane F. Because the samples were loaded properly into the gel - as 
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detennined by the visualization of the bands in lane F - the problem was thought to be due to the 
plasmid DNA concentration being too dilute. 
It is probable as well that because the sample volume for each lane was so small, not all the 
materials were transferred into the loading wells. For instance, if some ofthe DNA sample was 
accidently loaded onto the side of the eppendorftube, as opposed to the very bottom, it is likely 
that the DNA and metal complex would not be able to completely interact during the incubation 
period. Additionally we run the risk of not fully transferring the entire sample into the well. 
Thus it was beneficial to centrifuge each sample prior to incubation, and if necessary, prior to 
loading, to ensure that all components were properly transferred into the _well. 
By and large the agarose gel electrophoresis experiment was met with some success when the 
concentration of the DNA was increased relative to the metal complex concentration. As 
highlighted in Figure 19, bands were able to be visualized when the concentration of the plasmid 
DNA was increased relative to metal complex 1. Although the presence of bands in the sample 
lanes is encouraging, further analysis revealed that it was unlikely that our metal complex 
interacted with the DNA. Note that lane F corresponds to a control sample which was incubated 
under identical experimental conditions, albeit containing only plasmid DNA - no metal 
complex. The reader is directed to also consider how the location of the bands in sample lanes 
A, Band D match up exactly with the bands in control lane F. (Lack ofbands in sample lanes C 
and E are likely due to an operator loading error.) As stated earlier, we would expect that should 
the metal complex have an interaction with the DNA, a change will be induced in the DNA 
structure and thus the migration of the metal-DNA sample through the agarosc matrix should 
differ from the migration of the DNA sample. In other words, because the electrophoretic 
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mobility pattern of the metal-DNA sample matches well with the mobility pattern of the control 
lane, there is no evidence of an interaction between the metal complex and the plasmid DNA. 
Lanea A B C D E F G 
Figure 19. Sample gel image of plasmid DNA and increasing concentrations of complex !loaded from 
the right to the left. Lane G: 100 base pair marker. Lane F: control sample with only plasmid DNA, 
which was incubated under identical conditions. Lane E: least concentrated metal complex added to 
plasmid DNA. Lane A: most concentrated metal complex added to the plasmid DNA. Similar gels with 
clear band fonnation have not been obtained for complexes 2 and 3. 
Although the visuali7.ation of bands has been obtained for experiments using complex 1 and 
plasmid DNA, similar results have not been obtained using complexes 2 or 3. It should be noted 
that this experiment is extremely sensitive to various experimental conditions, including, but not 
limited to, sample concentrations, sample incubation period, run time on the gel and the voltage 
applied to the gel. It is probable that no bands have been visualized for the other metal 
complexes with added substituents because experimental conditions are not optimal. 
For purposes of comparison, consider the gel electrophoretic mobility pattern of pBR322 
plasmid DNA with palladium and platinum metal complexes as reported by Ruiz et a/. (Figure 
20).55 Lane 1 served as their DNA control and after visualization of the gel under UV light, they 
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noted the complexes ability to decrease the mobility of the DNA. The authors proposed that 
their complex had a direct impact on the tertiary structure of the DNA, inducing a change in both 
the open form (OC) and the covalently closed circular form (CCC) of plasmid DNA. 
Lanea 1 2 3 4 5 6 7 
oc 
CCC 
Figure 20. Agarose gel electrophoretic mobility pattern of plasmid DNA with various palladium and 
platinum metal complexes. Lane 1: plasmid DNA control. Sample lanes 2-7: plasmid DNA with various 
metal complexes. OC = open form of plasmid DNA, CCC = covalently closed circular form of plasmid 
DNA. Figure adopted from results published by Ruiz and co-workers." 
4. Summary of fmdings 
4.1 . Conclusion 
Three novel ruthenium terpyridine complexes with the formula cis-
[Ru(Terpy)(HPB)(OH2)](PF6) 1, cis-[Ru(Phterpy)(HPB)(OH2)](PF6) 2 and cis-
[Ru(Tterpy)(HPB)(OH2)](PF6) 3 have been synthesized and characterized by various 
spectroscopic means. 
In order to evaluate the ability of the complex to interact with CT-DNA, absorption 
spectroscopy experiments as well as time-lapsed kinetics and competitive binding displacement 
assays with ethidium bromide were performed. In order to further evaluate the interaction of the 
metal complexes with plasmid DNA, agarose gel electrophoresis was performed and results 
obtained for complex 1 suggested that there was no interaction between the complex and the 
DNA. It might be interesting to adjust the incubation period of the complex and DNA from one 
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hour to fourteen hours, as suggested by Desphande and co~workers. They also report positive 
gel results with using a wider range of metal complex concentrations (1 0-70 uM). 42 
4.2. Future Work 
For the immediate future, effort should be directed to learn how to harvest plasmid DNA. 
"Kits" available in the biology department enable the competent scientist to avoid buying 
plasmid DNA through commercial sources, but instead, to make it themselves. Because this 
reagent is costly it puts a lot of pressure to ensure that every experiment which uses the DNA 
yields meaningful results. Learning how to harvest the source in excess would allow for greater 
freedom to vary experimental conditions. 
• Correct absorption titration for other complexes l and 3 
o As proposed by Holmin et al. a more intense concentration difference 
between the metal complex and the DNA might yield better results. 25 
For example, Ru 20 uM; CT -DNA 0-280 uM. 
• Work out problems with gel electrophoresis 
o Try longer incubation (maybe 24 hours); add H202prior to incubation 
period 
o Higgins and co-workers obtained positive results when they varied the 
concentration o(the DNA, not the ~etal complex. 53 Other than this 
minor adaption the experimental conditions between our work and theirs 
were very similar. 
It would be interesting to explore the biological effects of the metal complexes with vario.us 
biomolecules. Collaboration with the biology department may allow for the cytotoxicity activity 
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of our metal complexes toward cisplatin resistant cancer cells to be evaluated. It would be 
especially interesting to compare the complexes' calculated resistance factors (RF) to that of 
cisplatin (RF = 5.61).56 
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5. Appendix 
Appendlx.l. Crystal data and structure refinement for tran.r-[Ru(Phterpy)(HPB)Cl](PF6) •2H20 
Identification code ha13_0m 
Empirical formula C~15.4t CIF~"0,.2tPRu 
Formula weight 822.76 
Temperature (K) 100(2) 
Wavelength (A) 0.71073 
Crystal system Triclinic 
Space group P-1 
Unit cell dimensions 
a(A) 10.1967(3) 
b (A) 11.9503(4) 
c(A) 14.1934(5) 
a(") 112.8086(4) 
P<o:l 91.7830(4) 
y(") 95.5838(4) 
V(A3) 1582.24(9) 
z 2 
Dca~c (Mg mol) 1.727 
Absorption coefficient (mm'1) 0.711 
F(OOO) 826 
Crystal size {mm3) 0.47 X 0.43 X 0.23 
8 range for data collection (") 1.90 to 29.57 
Index ranges -14 s h :s: 14, -16 :s: k :s: 16, -19 s 1 s 19 
Reflections collected 3.S319 
Independent reflections 8852 [Ra:: 0.0153] 
Completeness to 8 = 29.57° (0.4) 99.7 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8541 and 0.7319 
Refinement method Full-matrix least squares on F2 
Data I restraints I parameters 8852 12821 537 
Goochless-of-fit on F2 1.030 
Final R indices [I > 2a(f)] Rt - 0.0229, wR1 • 0.0599 
R indices (all data) R1 • 0.0241, wRz = 0.0609 
Largest difference peak and hole (e.A-3) 1.569 and -0.387 
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Appendix 2. Selected interatomic distances (A) and angles (<I) for 
complex trans-[Ru(Phterpy)(HPB)Cl](PF6)·2H20 
Bond Lengths, A 
. Ru(l)-N(2} 1.9606(11) 
Ru(l)-0(1) 1.9646(10) 
Ru(1)-N(3) 2.0542(11) 
Ru(l)-N(4) 2.0881(11) 
Ru(1)-N(1) 2.0882(11) 
Ru(1)-Cl(l) 2.3536(3) 
Bond Angles, o 
N(2}-Ru(l)-C>(l) 88.19(4) 
N(2)-Ru(1)-N(3) 79.69(4) 
()(1)-Ru(1)-N(3) 90.64(4) 
N(2)-Ru(l)-N(4) 177.01(4) 
0(1)-Ru(1)-N(4) 88.83(4) 
N(3)-Ru(1)-N(4) 100.29(4) 
N(2)-Ru(l )-N(1) 80.09(4) 
(){1)-Ru(1)-N(1) 89.80(4) 
N(3)-Ru{l)-N(l) 159.75(4) 
N(4)-Ru(l)-N(l) 99.97(4) 
N(2)-Ru(l)-Cl(l) 87.80(3) 
()(1)-Ru(l)-Cl(l) 175.70(3) 
N(3)-Ru(l)-Cl(l) 90.17(3) 
N(4)-Ru(l)-Cl(l) 95.19(3) 
N(1)-Ru(l)-Cl(l) 87.98(3) 
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